1. ScholarBank@NUS
  2. 1. Staff
  3. Staff Publications
Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/25751
DC FieldValue
dc.titleIn vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor
dc.contributor.authorZhou, J.
dc.contributor.authorKhng, J.
dc.contributor.authorJasinghe, V.J.
dc.contributor.authorBi, C.
dc.contributor.authorPoon, L.F.
dc.contributor.authorXie, Z.
dc.contributor.authorChen, C.-S.
dc.contributor.authorNeo, C.H.S.
dc.contributor.authorPan, M.
dc.contributor.authorYu, H.
dc.contributor.authorYeoh, A.E.-J.
dc.contributor.authorLu, Y.
dc.contributor.authorGlaser, K.B.
dc.contributor.authorAlbert, D.H.
dc.contributor.authorDavidsen, S.K.
dc.date.accessioned2011-08-16T07:52:39Z
dc.date.available2011-08-16T07:52:39Z
dc.date.issued2008
dc.identifier.citationZhou, J., Khng, J., Jasinghe, V.J., Bi, C., Poon, L.F., Xie, Z., Chen, C.-S., Neo, C.H.S., Pan, M., Yu, H., Yeoh, A.E.-J., Lu, Y., Glaser, K.B., Albert, D.H., Davidsen, S.K. (2008). In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leukemia Research 32 (7) : 1091-1100. ScholarBank@NUS Repository.
dc.identifier.issn01452126
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/25751
dc.description.abstractNeoangiogenesis plays an important role in leukemogenesis. We investigated the in vivo anti-leukemic effect of ABT-869 against AML with wild-type FLT3 using RFP transfected HL60 cells with in vivo imaging technology on both the subcutaneous and systemic leukemia xenograft models. ABT-869 showed a five-fold inhibition of tumor growth in comparison with vehicle control. IHC analysis revealed that ABT-869 decreased p-VEGFR1, Ki-67 labeling index, VEGF and remarkably increased apoptotic cells in the xenograft models. ABT-869 also reduced the leukemia burden and prolonged survival. Our study supports the rationale for clinically testing an anti-angiogenesis agent in AML with wild-type FLT3. © 2007 Elsevier Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.leukres.2007.11.025
dc.sourceScopus
dc.subjectAcute myeloid leukemia
dc.subjectIn vivo
dc.subjectTyrosine kinase inhibitor
dc.subjectWhole-body imaging technology
dc.subjectWild-type FLT3 receptor
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.contributor.departmentPHYSIOLOGY
dc.contributor.departmentPAEDIATRICS
dc.description.sourcetitleLeukemia Research
dc.description.volume32
dc.description.issue7
dc.description.page1091-1100
dc.identifier.isiut000255856000013
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.